Oruka Therapeutics, Inc. SEC filings ORKA
Oruka Therapeutics, Inc. has 1,001 filings in SEC EDGAR's recent list, going back to Jun 26, 2009. Its latest annual report, Form ARS, was filed on Apr 17, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 10, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 26, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 17, 2026 | — |
| DEF 14A | Proxy statement | Apr 17, 2026 | Jun 2, 2026 |
| DEFA14A | Additional proxy material | Apr 18, 2025 | — |
| DEF 14A | Proxy statement | Apr 18, 2025 | Jun 2, 2025 |
| DEF 14A | Proxy statement | Oct 18, 2024 | Nov 14, 2024 |
| PRE 14A | Preliminary proxy statement | Oct 7, 2024 | Nov 14, 2024 |
| DEFA14A | Additional proxy material | Dec 19, 2023 | — |
| DEF 14A | Proxy statement | Dec 19, 2023 | Jan 30, 2024 |
| DEFA14A | Additional proxy material | Nov 3, 2022 | — |
| DEF 14A | Proxy statement | Nov 3, 2022 | Dec 15, 2022 |
| DEFA14A | Additional proxy material | Jun 28, 2021 | — |
| DEFA14A | Additional proxy material | Apr 21, 2021 | — |
| DEF 14A | Proxy statement | Apr 21, 2021 | Jun 10, 2021 |
| DEFA14A | Additional proxy material | Dec 9, 2020 | — |
| DEFA14A | Additional proxy material | Oct 28, 2020 | — |
| DEF 14A | Proxy statement | Oct 28, 2020 | Dec 10, 2020 |
| DEFA14A | Additional proxy material | Oct 25, 2019 | — |
| DEF 14A | Proxy statement | Oct 25, 2019 | Dec 10, 2019 |
| DEF 14A | Proxy statement | Sep 20, 2018 | Oct 18, 2018 |
| PRE 14A | Preliminary proxy statement | Sep 10, 2018 | Sep 10, 2018 |
| DEFA14A | Additional proxy material | Apr 18, 2018 | — |
| DEF 14A | Proxy statement | Apr 18, 2018 | May 31, 2018 |
| DEFA14A | Additional proxy material | Apr 21, 2017 | — |
| DEF 14A | Proxy statement | Apr 21, 2017 | Jun 1, 2017 |
| DEFA14A | Additional proxy material | Apr 27, 2016 | — |
| DEF 14A | Proxy statement | Apr 27, 2016 | Jun 9, 2016 |
| DEFA14A | Additional proxy material | Jun 11, 2015 | — |
| DEF 14A | Proxy statement | Apr 14, 2015 | Jun 4, 2015 |
| PRE 14A | Preliminary proxy statement | Mar 27, 2015 | Jun 4, 2015 |
| DEFA14A | Additional proxy material | Apr 15, 2014 | — |
| DEF 14A | Proxy statement | Apr 15, 2014 | Jun 5, 2014 |
| DEFA14A | Additional proxy material | Aug 1, 2013 | — |
| DEF 14A | Proxy statement | Aug 1, 2013 | Sep 17, 2013 |
| DEF 14A | Proxy statement | Feb 1, 2013 | Feb 25, 2013 |
| PRE 14A | Preliminary proxy statement | Jan 16, 2013 | Jan 16, 2013 |
| DEFA14A | Additional proxy material | Apr 5, 2012 | — |
| DEF 14A | Proxy statement | Apr 5, 2012 | May 25, 2012 |
| DEFA14A | Additional proxy material | Mar 30, 2011 | — |
| DEF 14A | Proxy statement | Mar 30, 2011 | May 20, 2011 |
| DEFA14A | Additional proxy material | Apr 7, 2010 | — |
| DEF 14A | Proxy statement | Apr 7, 2010 | May 21, 2010 |
Showing 41 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ORKA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Menlo Park, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 907654
- Former names
- ARCA biopharma, Inc. (until Aug 30, 2024); NUVELO INC (until Jan 27, 2009); HYSEQ INC (until Jan 28, 2003)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.